Intelligence Feed event · Policy · 2026-10-14

    Rhythm Pharmaceuticals Launches IMCIVREE in Japan Following NHI Pricing

    Question

    Rhythm Pharmaceuticals Launches IMCIVREE in Japan Following NHI Pricing

    Direct answer

    Rhythm Pharmaceuticals began commercial distribution of IMCIVREE (setmelanotide) in Japan after securing MHLW authorization and NHI pricing coverage. The product becomes the only approved therapy in the Japanese market targeting acquired hypothalamic obesity.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-14
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Rhythm Pharmaceuticals Launches IMCIVREE in Japan Following NHI Pricing”, revision 1, evidence through 2026-10-14. https://marketontology.com/market-events/2026-10-14/rhythm-pharmaceuticals-launches-imcivree-in-japan-following-nhi-pricing-6c21d4

    POLICY
    Rhythm Pharmaceuticals Launches IMCIVREE in Japan Following NHI Pricing
    Rhythm Pharmaceuticals began commercial distribution of IMCIVREE (setmelanotide) in Japan after securing MHLW authorization and NHI pricing coverage. The product becomes the only approved therapy in the Japanese market targeting acquired hypothalamic obesity.
    RYTM
    Impact
    63
    OCT 14
    SIG
    90%
    RYTM
    Rhythm Pharmaceuticals Launches IMCIVREE in Japan Following NHI Pricing
    Rhythm Pharmaceuticals began commercial distribution of IMCIVREE (setmelanotide) in Japan after securing MHLW authorization and NHI pricing coverage. The product becomes the only approved therapy in the Japanese market targeting acquired hypothalamic obesity.
    → National Health Insurance reimbursement listing establishes commercial pricing and direct market access across Japan.
    Impact
    Rhythm Pharmaceuticals began commercial distribution of IMCIVREE (setmelanotide) in Japan after securing MHLW authorization and NHI pricing coverage. The product becomes the only approved therapy in the Japanese market targeting acquired hypothalamic obesity.
    Affected
    RYTM
    Transmission
    National Health Insurance reimbursement listing establishes commercial pricing and direct market access across Japan.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RYTMcommercial expansion into Asia via Japanese NHI reimbursement listingUp1-3mCommercial launch of IMCIVREE in Japan following MHLW approval and inclusion on NHI price list.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month